Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG) (ECLIPSE-NTG)

May 5, 2014 updated by: The Medicines Company

Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG)

The purpose of this study is to establish the safety of clevidipine in the treatment of perioperative hypertension. Approximately 500-900 patients with perioperative hypertension undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nitroglycerin.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary objective was to establish the safety of clevidipine in the treatment of perioperative hypertension, as assessed by comparing the incidences of death, stroke, MI and renal dysfunction in the clevidipine and nitroglycerin treatment groups from the initiation of study drug infusion through postoperative Day 30. Secondary objectives were to evaluate the efficacy of study drug, assessed by the blood pressure (BP) lowering effect, and additional safety variables.

Study Type

Interventional

Enrollment (Actual)

629

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35209
        • Brookwood Medical Center
      • Birmingham, Alabama, United States, 35213
        • Baptist Medical Center, Montclair
      • Birmingham, Alabama, United States, 35235
        • Medical Center East
      • Montgomery, Alabama, United States, 36116
        • Baptist Medical Center, South
    • Arizona
      • Tucson, Arizona, United States, 85724
        • University Medical Center
    • California
      • Laguna Hills, California, United States, 92653
        • Saddleback Memorial Medical Center
      • Los Angeles, California, United States, 90033
        • Keck School of Medicine, University of Southern California
      • Pasadena, California, United States, 91109
        • Huntington Memorial Hospital
      • San Francisco, California, United States, 94143-0648
        • University of California
    • Florida
      • Hudson, Florida, United States, 34667
        • Regional Medical Center - Bayonet Point
      • Melbourne, Florida, United States, 32901
        • Health First Holmes Regional Medical Center
      • Pensacola, Florida, United States, 32504
        • Sacred Heart Health System
    • Hawaii
      • Honolulu, Hawaii, United States, 96817
        • Kaiser Permanente Moanalua Medical Center
    • Illinois
      • Evanston, Illinois, United States, 60202
        • Saint Francis Hospital
    • Kansas
      • Wichita, Kansas, United States, 67214
        • Wesley Medical Center
    • Maryland
      • Towson, Maryland, United States, 21204
        • St Joseph Medical Center
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Henry Ford Health System
    • New York
      • New York, New York, United States, 10016
        • New York University Medical Center
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • Sterling Research Group, Ltd.
      • Cincinnati, Ohio, United States, 45219
        • The Christ Hospital, The Linder Clinical Trial Center
    • Oregon
      • Portland, Oregon, United States, 97239
        • Portland VA Medical Center
    • Texas
      • Houston, Texas, United States, 77030
        • The Methodist Hospital
      • Houston, Texas, United States, 77024
        • Memorial Herman Memorial City Hospital
      • Houston, Texas, United States, 77090
        • Houston Northwest Medical Center
      • Houston, Texas, United States, 77030-4211
        • Michael E DeBakey VA Medical Center
    • Virginia
      • Falls Church, Virginia, United States, 22042
        • Inova Fairfax Hospital
      • Richmond, Virginia, United States, 23298
        • Virginia Commonwealth University Medical Center
    • Washington
      • Tacoma, Washington, United States, 98405
        • Saint Joseph Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Prerandomization Inclusion Criteria:

  • Provide written informed consent before initiation of any study related procedures.
  • Be at least 18 years of age
  • Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery

Prerandomization Exclusion Criteria:

  • Women of child-bearing potential (unless they have a negative pregnancy test)
  • Recent cerebrovascular accident (within 3 months before randomization)
  • Known intolerance to calcium channel blockers
  • Known or suspected hypersensitivity to nitroglycerin
  • Allergy to soybean oil or egg lecithin (components of the lipid vehicle)
  • Pre-existing permanent ventricular pacing
  • Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial
  • Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study

Postrandomization Inclusion Criteria:

  • Determined to be hypertensive perioperatively as determined by the investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: clevidipine
Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
Drug: clevidipine
Other Names:
  • clevidipine, Cleviprex
Active Comparator: nitroglycerin
Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
Drug: nitroglycerin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of death, stroke, MI and renal dysfunction
Time Frame: Initiation of study drug infusion through post-operative Day 30
Initiation of study drug infusion through post-operative Day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Medicines Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2004

Primary Completion (Actual)

March 1, 2005

Study Completion (Actual)

April 1, 2005

Study Registration Dates

First Submitted

October 7, 2004

First Submitted That Met QC Criteria

October 7, 2004

First Posted (Estimate)

October 8, 2004

Study Record Updates

Last Update Posted (Estimate)

May 6, 2014

Last Update Submitted That Met QC Criteria

May 5, 2014

Last Verified

May 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TMC-CLV-03-03

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on clevidipine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe